Skip to content
10-Q

Quarterly Report

INVIVO THERAPEUTICS HOLDINGS CORP.

0001558370-23-009616

← back to feed
Filed
May 12, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2023 · May 8, 2023 3.11M sh
Shares Diluted Q1 2023 · Mar 31, 2023 2.74M sh
Shares Diluted Q1 2023 · Mar 31, 2022 1.37M sh
Capex Q1 2023 · Mar 31, 2023 $21K
Capex Q1 2023 · Mar 31, 2022 $26K
Operating Cash Flow Q1 2023 · Mar 31, 2023 −$3.2M
Operating Cash Flow Q1 2023 · Mar 31, 2022 −$3.83M
Cash And Equivalents Q1 2023 · Mar 31, 2023 $13.15M
Cash And Equivalents Q1 2023 · Dec 31, 2022 $16.35M
Stockholders Equity Q1 2023 · Mar 31, 2023 $13.48M
Stockholders Equity Q1 2023 · Dec 31, 2022 $15.75M
Stockholders Equity Q1 2023 · Mar 31, 2022 $15.52M
Stockholders Equity Q1 2023 · Dec 31, 2021 $18.12M
Current Liabilities Q1 2023 · Mar 31, 2023 $1.65M
Current Liabilities Q1 2023 · Dec 31, 2022 $2.42M
Total Liabilities Q1 2023 · Mar 31, 2023 $2.18M
Total Liabilities Q1 2023 · Dec 31, 2022 $3.08M
Current Assets Q1 2023 · Mar 31, 2023 $14.61M
Current Assets Q1 2023 · Dec 31, 2022 $17.6M
Total Assets Q1 2023 · Mar 31, 2023 $15.65M
Total Assets Q1 2023 · Dec 31, 2022 $18.82M
Eps Diluted Q1 2023 · Mar 31, 2023 −$0.85
Eps Diluted Q1 2023 · Mar 31, 2022 −$1.94
Eps Basic Q1 2023 · Mar 31, 2023 −$0.85
Eps Basic Q1 2023 · Mar 31, 2022 −$1.94
Sga Expense Q1 2023 · Mar 31, 2023 $1.11M
Sga Expense Q1 2023 · Mar 31, 2022 $1.23M
Rd Expense Q1 2023 · Mar 31, 2023 $1.38M
Rd Expense Q1 2023 · Mar 31, 2022 $1.43M
Net Income Q1 2023 · Mar 31, 2023 −$2.33M
Net Income Q1 2023 · Mar 31, 2022 −$2.66M
Operating Income Q1 2023 · Mar 31, 2023 −$2.49M
Operating Income Q1 2023 · Mar 31, 2022 −$2.67M